Bayer AG entered into an antibody discovery, option, and license agreement with Twist Bioscience, a company offering high-quality synthetic DNA using its silicon platform. The company’s “Library of Libraries,” a collection of synthetic antibody libraries that harnesses innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to increase the probability of success of ...